CDSCO requests manufacturers to increase the manufacturing and import of in-vitro diagnostics kits.

The Central Drugs Standard Control Organization vide its notification dated 29th April 2021 has requested all the manufacturers/importers to increase manufacturing/import of in-vitro diagnostic testing reagents/kits to maximum capacity and at fast pace in light of increasing cases of covid-19 positive cases.

The Patients who are COVID-19 positive may require testing for inflammatory markers such as IL-6, D-Dimer and CRP.The result of these important tests directly dictate the management of COVID-19 patients by the physicians to take further timely decisions.

Further the manufacturers shall submit information about the reagents/kits manufactured, current stock and the capacity to manufacture and proposed capacity to CDSCO.

RECENT UPDATES

Measures to aid MSME EXPORTERS

Raising and Accelerating MSME Performance (RAMP) Scheme aims to provide support to Micro, Small and Medium enterprises through increased access to technological upgradation, market and

Read More »